Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer

Journal of Nuclear Medicine

Volumn 48, Issue 9, 2007, Pages 1501-1510

  Sampath, Lakshmi ^a   Kwon, Sunkuk ^a   Ke, Shi ^a   Wang, Wei ^a   Schiff, Rachel ^a   Mawad, Michel E ^a   Sevick Muraca, Eva M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Dual labeling; HER2 overexpression; Near infrared optical imaging; Trastuzumab

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; HEMATOXYLIN; IMMUNOGLOBULIN G PENTETIC ACID INDIUM 111; INDIUM 111; PENTETIC ACID; TRASTUZUMAB; TRASTUZUMAB PENTETIC ACID INDIUM 111; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER DIAGNOSIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOICHIOMETRY;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 34548567115     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042234     Document Type: Article

References (31)

1. Houston JP, Ke S, Wang W, Li C, Sevick-Muraca EM. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt. 2005;10:054010.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
3. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285-4289.
4. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23:391-409.
5. Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol. 2006;11:199-208.
6. Regitnig P, Schippinger W, Lindbauer M, Samonigg H, Lax SF. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol. 2004;203:918-926.
7. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 2001;93:1141-1146.
8. Pectasides D, Gaglia A, Arapantoni-Dadioti P, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res. 2006;26:647-653.
9. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer. 2005;103:1763-1769.
10. Carlsson J, Nordgren H, Sjostrom J, et al. HER2 expression in breast cancer primary tumours and corresponding metastases: original data and literature review. Br J Cancer. 2004;90:2344-2348.
11. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
12. 90Y using a bifunctional DTPA chelating agent. Cancer Biother Radiopharm. 2003;18:355-363.
13. Tang Y, Wang J, Scollard DA, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51-58.
14. Dennis MS, Jin H, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 2007;67:254-261.
15. Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun. 2005;26:427-432.
16. Hilger I, Leistner Y, Berndt A, et al. Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol. 2004;14:1124-1129.
17. Watanabe TM, Tada H, Higuchi H, Ohuchi N. Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining. Biochem Biophys Res Commun. 2006;351:7-13.
18. Tada H, Higuchi H, Watanabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007;67:1138-1144.
19. Huh YM, Jun YM, Song HT, et al. In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals. J Am Chem Soc. 2005;127:12387-12391.
20. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med. 2003;49:403-408.
21. Copland JA, Eghtedari M, Popov VL, et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol. 2004;6:341-349.
22. Perik PJ, Lub-de Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276-2282.
23. Lindmo T, Boven E, Cuttitta F, Fedorka J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
24. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001;345:995-996.
25. 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99-106.
26. Querzoli P, Pedriali M, Rinaldi R, et al. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res. 2006;12:6696-6701.
27. Weinstein JN, Parker RJ, Keenan AM, Dower SK, Morse HC, Sieber SM. Monoclonal antibodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science. 1982;218:1334-1337.
28. Weinstein JN, Stellar MA, Keenan AM, et al. Monoclonal antibodies in the lymphatics: selective delivery to lymph node metastases of a solid tumor. Science. 1983;222:423-426.
29. Steller MA, Parker RJ, Covell DG, et al. Optimization of monoclonal antibody delivery via the lymphatics: the dose dependence. Cancer Res. 1986;46:1830-1834.
30. Sharma R, Wang W, Rasmussen JC, et al. Quantitative imaging of lymph function. Am J Physiol Heart Circ Physiol. 2007;292:H3109-H3118.
31. Sevick-Muraca EM, Sharma R, Rasmussen JC, et al. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore. Radiology. Accepted.